Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Naples – page 50

1 202 clinical trials in Naples, Italy across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Naples at a glance
1 202
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

1 202 trials in Naples

Open in trial search

Non-small cell lung cancer+1

Not yet recruiting

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Neoplasm malignant

Not yet recruiting

Study on the Effectiveness and Safety of Luveltamab Tazevibulin Compared to Chemotherapy in Women with Relapsed Platinum-resistant Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Sutro Biopharma Inc.

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Oncoc4 Inc.

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing Ivonescimab and Chemotherapy with Pembrolizumab and Chemotherapy for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Summit Therapeutics Inc.

Tuberculosis

Not yet recruiting

Study on the Safety and Tolerability of Higher Dose Rifampicin for Tuberculosis Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Rifampicin

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Transitional cell carcinoma

Not yet recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Major depression+2

Not yet recruiting

Study on Enhanced Treatment for Schizophrenia, Depression, and Bipolar Disorder Using Esketamine, Bupropion, and Quetiapine for Patients with Initial Treatment Failure

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Clozapine
  • Sponsor:Universitair Medisch Centrum Utrecht

Renal cell carcinoma

Not yet recruiting

Study comparing XL092 plus nivolumab versus sunitinib for patients with advanced or metastatic non-clear cell kidney cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Exelixis Inc.

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Naples

What the registry says about research in the country

01 Respiratory Diseases

Research focusing on pulmonary conditions including innovative treatments for idiopathic pulmonary fibrosis and COPD. Studies evaluate new medications like tezepelumab and investigate respiratory syncytial virus vaccines for older adults.

  • Idiopathic Pulmonary Fibrosis
  • COPD Management
  • RSV Prevention

Clinical trials aim to improve lung function and reduce disease progression in patients with chronic respiratory conditions.

02 Oncology Research

Comprehensive studies targeting various cancer types, with emphasis on targeted therapies and immunological approaches. Investigations include treatments for colorectal, gastric, and lung cancers.

  • Breast Cancer Prevention
  • Gastrointestinal Cancers
  • Advanced Solid Tumors

Novel therapeutic combinations and precision medicine approaches are being evaluated for improved patient outcomes.

03 Chronic Diseases

Studies addressing kidney disease, cardiovascular conditions, and neurological disorders. Innovative treatments for Parkinson's disease and end-stage kidney disease are under investigation.

  • Kidney Disease Management
  • Heart Failure Prevention
  • Neurological Disorders

Research focuses on developing safer and more effective treatments for chronic conditions affecting quality of life.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.